Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print December 16, 2005, doi:10.1212/01.wnl.0000192102.41141.9e)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000192102.41141.9ev1
66/1_suppl_1/S79    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, Y.
Received ,
Accepted ,

Apolipoprotein E and Alzheimer disease

Yadong Huang MD, PhD*

From the Gladstone Institute of Neurological Disease, the Gladstone Institute of Cardiovascular Disease, and the Departments of Pathology and Neurology, University of California, San Francisco, CA.


* To whom correspondence should be addressed. E-mail: yhuang{at}gladstone.ucsf.edu.

Abstract--Apolipoprotein (apo) E, a multifunctional protein with central roles in lipid metabolism and neurobiology, has three common isoforms (apoE2, apoE3, and apoE4) with different effects on lipid homeostasis and neurobiology. Unlike apoE3, the most common isoform, apoE4, is associated with increased risk of developing Alzheimer disease (AD) and other neurodegenerative disorders. Although the mechanisms underlying apoE4’s action in AD pathogenesis are still poorly understood, emerging data strongly suggest that apoE4 contributes to this disease by interacting with different factors through various pathways. Thus, multiple molecular and cellular mechanisms should be considered when anti-AD drugs are developed based on apoE studies.




This article has been cited by other articles:


Home page
 J. Neurosci.Home page
Q. Xu, D. Walker, A. Bernardo, J. Brodbeck, M. E. Balestra, and Y. Huang
Intron-3 Retention/Splicing Controls Neuronal Expression of Apolipoprotein E in the CNS
J. Neurosci., February 6, 2008; 28(6): 1452 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Brodbeck, M. E. Balestra, A. M. Saunders, A. D. Roses, R. W. Mahley, and Y. Huang
Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons
PNAS, January 29, 2008; 105(4): 1343 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
X. He, K. Cooley, C. H. Y. Chung, N. Dashti, and J. Tang
Apolipoprotein Receptor 2 and X11{alpha}/{beta} Mediate Apolipoprotein E-Induced Endocytosis of Amyloid-{beta} Precursor Protein and {beta}-Secretase, Leading to Amyloid-{beta} Production
J. Neurosci., April 11, 2007; 27(15): 4052 - 4060.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Q. Xu, A. Bernardo, D. Walker, T. Kanegawa, R. W. Mahley, and Y. Huang
Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus.
J. Neurosci., May 10, 2006; 26(19): 4985 - 4994.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. E. Finch
A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes
Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.